Bioharvest Sciences (BHST) closed at $1.72 on October 23, 2026, up 2.4% from the previous close, on volume of 25,140 shares (30-day average 22,838).
Data as of October 23, 2026.
Newsfile (Tue, 13-Oct 7:00 AM ET)
Tate & Lyle and Bioharvest Reach Key Milestone in Next-Generation Sweetener Development Programme
Newsfile (Thu, 8-Oct 8:00 AM ET)
BioHarvest Sciences Announces Share Repurchase Program
Newsfile (Tue, 29-Sep 7:02 AM ET)
Newsfile (Tue, 15-Sep 7:01 AM ET)
BioHarvest Sciences to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Newsfile (Mon, 14-Sep 7:01 AM ET)
BioHarvest Sciences Registers for Dual Listing on the Tel Aviv Stock Exchange (TASE)
Newsfile (Thu, 3-Sep 7:01 AM ET)
BioHarvest Reports Second Quarter 2026 Financial Results and Provides Business Update
Newsfile (Tue, 11-Aug 6:30 AM ET)
BioHarvest Secures 20-Ton Manufacturing and Supply Agreement for Rare Botanical Luxury Fragrance
Newsfile (Tue, 11-Aug 6:00 AM ET)
BioHarvest Sciences to Present at the Canaccord Genuity 46th Annual Growth Conference
Newsfile (Wed, 29-Jul 8:00 AM ET)
BioHarvest Sciences to Report Second Quarter 2026 Financial Results on August 11, 2026
Newsfile (Tue, 28-Jul 8:00 AM ET)
BioHarvest Sciences Inc is the developer and owner of the patented bio-cell growth platform farming technology. The Company has two operating segments or business units: the Products business unit and the CDMO Services business unit. In identifying these operating segments, management generally follows the Company's service lines representing its main products and services. The Products Business Unit - Nutraceuticals: Research, development, manufacturing, marketing and sales of science-based health and wellness nutraceutical solutions which are manufactured and sold as dietary supplements, functional food and beverages. The CDMO Services Business Unit - comprising a Contract Development and Manufacturing Operation that offers pharmaceuticals, cosmeceuticals, nutraceuticals, and nutritions.
Bioharvest Sciences trades on the NASDAQ stock market under the symbol BHST.
As of October 23, 2026, BHST stock price climbed to $1.72 with 25,140 million shares trading.
BHST has a beta of 2.15, meaning it tends to be more sensitive to market movements. BHST has a correlation of 0.13 to the broad based SPY ETF.
BHST has a market cap of $38.97 million. This is considered a Sub-Micro Cap stock.
Last quarter Bioharvest Sciences reported $9 million in Revenue and -$.17 earnings per share. This fell short of revenue expectation by $-699,800 and missed earnings estimates by -$.05.
BHST has underperformed the market in the last year with a return of -85.5%, while the SPY ETF gained +14.3%. In the last 3 month period, BHST fell short of the market, returning -14.0%, while SPY returned +3.2%. However, in the most recent 2 weeks BHST has outperformed the stock market by returning +3.6%, while SPY returned -2.4%.
BHST support price is $1.56 and resistance is $1.80 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BHST shares will trade within this expected range on the day.
